RxDoctor Payments Data

Jon Raso, MD

Internal Medicine · Mount Bethel, PANPI 1609080175

Payments from drug & device makers

$20,745in general payments, 2019–2025

Across 1,545 payments — averaging $13.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$2K
  • Amgen$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • GSK$1K
  • Pfizer$1K
  • plus $12K from 54 others

What the payments were for

  • Food & beverage$20,23398%
  • Education$5122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca113$2,086
AbbVie(2 entities)131$1,670
Amgen(2 entities)119$1,540
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC177$1,266
GSK75$1,120
Pfizer125$1,116
Lilly USA, LLC97$1,114
Novo Nordisk102$1,088
Astellas Pharma US Inc30$959
Boehringer Ingelheim50$800
Merck45$710
Takeda Pharmaceuticals U.S.A., Inc.60$685
Johnson & Johnson58$656
Bausch Health US, LLC33$636
Amarin Pharma, Inc.50$601
Novartis26$435
Sanofi-aventis U.S. LLC29$415
Bayer14$266
Biocryst US Sales Co., LLC14$264
Esperion Therapeutics, Inc.15$257
Kowa Pharmaceuticals America, Inc.15$213
Mannkind Corporation15$206
Paratek Pharmaceuticals, Inc.11$197
Exact Sciences7$184
Shield Therapeutics Inc11$173
Lundbeck LLC9$166
Medtronic9$151
Teva Pharmaceuticals USA, Inc.10$143
Philips North America LLC10$141
Otsuka America Pharmaceutical, Inc.9$133
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$102
Radius Health, Inc.6$99
Axsome Therapeutics, Inc.4$90
Alkermes, Inc.4$89
Biohaven Pharmaceutical Holding Company Ltd.5$86
Biohaven Pharmaceuticals, Inc.5$77
Almatica Pharma LLC4$76
Arbor Pharmaceuticals, Inc.5$76
CSL Behring3$73
Scilex Pharmaceuticals Inc.3$60
Melinta Therapeutics, LLC3$48
E.r. Squibb & Sons, L.L.C.3$45
Xeris Pharmaceuticals, Inc.3$42
Eisai Inc.3$42
Abbott2$39
Shire North American Group Inc2$37
Upsher-smith Laboratories LLC1$32
Mylan Specialty L.p.2$31
Avanir Pharmaceuticals, Inc.2$31
Biofire Diagnostics, LLC1$30
Endo USA, Inc.1$28
Phadia US Inc.1$18
Aytu Biopharma, Inc.1$18
Biodelivery Sciences International, Inc.1$15
Mission Pharmacal Company1$15
Idorsia Pharmaceuticals US Inc1$14
UCB, Inc.1$14
Sanofi Pasteur Inc.1$14
IBSA Pharma Inc.1$11
Sumitomo Pharma America, Inc.1$1

How this compares

$20,745 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$251,190
Medicare patients
921
Services billed
3,660

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban335$279,201
OzempicSemaglutide231$240,641
XareltoRivaroxaban166$124,566
JardianceEmpagliflozin116$122,082
FarxigaDapagliflozin Propanediol91$88,179
Breztri AerosphereBudesonide/Glycopyr/Formoterol82$58,891
MounjaroTirzepatide36$48,362
TradjentaLinagliptin54$47,792
GlyxambiEmpagliflozin/Linagliptin54$47,311
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$47,278
JanuviaSitagliptin Phosphate59$42,813
TrulicityDulaglutide46$40,952
Repatha SureclickEvolocumab38$39,069
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog31$38,257
Tresiba Flextouch U-200Insulin Degludec37$38,069

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Synjardy Xr, Jentadueto$800$286,518342 claims
PfizerEliquis$1,116$279,201335 claims
Novo NordiskOzempic, Rybelsus$1,088$255,764242 claims
AstraZenecaFarxiga, Breztri Aerosphere$2,086$147,070173 claims
Johnson & JohnsonXarelto$656$124,566166 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$1,120$93,467119 claims
MerckJanuvia, Janumet, Janumet Xr$710$89,972116 claims
Lilly USA, LLCMounjaro, Trulicity$1,114$89,31482 claims
NovartisEntresto$435$26,49324 claims
Otsuka America Pharmaceutical, Inc.Rexulti$133$22,97319 claims
Astellas Pharma US IncMyrbetriq$959$20,65538 claims
AmgenProlia$1,540$18,55011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Mount Bethel

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →